ALIA-1758 vs Remternetug

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline

ALIA-1758

Developed by AbbVie

Phase 1 in Alzheimer's Diseasemonoclonal antibody (BBB-crossing)
Weak signal

NCT06406348 · Phase 1 · completed

The trial was randomized and blinded against placebo, but it was conducted in healthy volunteers purely to check safety and dosing rather than cognitive or disease benefit, and no results have been posted yet.

No aligned efficacy figure on record for this race.

Remternetug

Developed by Eli Lilly

Phase 3 in Alzheimer's Diseasemonoclonal antibody
Partial signal

NCT05463731 · Phase 3 · completed

The study randomized 1,667 participants to remternetug or matching placebo, with participants and investigators blinded during the main treatment period. Its primary endpoint was amyloid plaque clearance measured by PET, a biomarker endpoint, and the registry does not report whether the week-52 comparison was favorable or statistically significant.

Next expected readout: April 2029 · NCT06653153 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALIA-1758Remternetug
CDR-SB, change—Not reported—Not posted · NCT05463731
ADAS-Cog11, change—Not reported—Not posted · NCT05463731
ADCS-ADL, change—Not reported—Not posted · NCT05463731
MMSE, change—Not reported—Not posted · NCT05463731
Amyloid PET, change (centiloids)—Not reported—Not posted · NCT05463731

CDR-SB, change

ALIA-1758
—Not reported
Remternetug
—Not posted · NCT05463731

ADAS-Cog11, change

ALIA-1758
—Not reported
Remternetug
—Not posted · NCT05463731

ADCS-ADL, change

ALIA-1758
—Not reported
Remternetug
—Not posted · NCT05463731

MMSE, change

ALIA-1758
—Not reported
Remternetug
—Not posted · NCT05463731

Amyloid PET, change (centiloids)

ALIA-1758
—Not reported
Remternetug
—Not posted · NCT05463731
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ALIA-1758: no structured comparison results are available for Alzheimer's Disease.

Remternetug: no structured comparison results are available for Alzheimer's Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALIA-1758's landscape · Remternetug's landscape